Qbrexza is a prescription medication used to treat primary axillary hyperhidrosis, a condition characterized by excessive sweating in the underarms [1]. It is an anticholinergic medication [1].
How does Qbrexza work?
Qbrexza contains the active ingredient topical glycopyrronium tosylate. It works by blocking the action of acetylcholine, a neurotransmitter that signals sweat glands to produce sweat [2]. When applied to the underarms, it reduces the amount of sweat produced [1][2].
What is the typical dosage and how is Qbrexza applied?
Qbrexza is available as a medicated cloth [1]. For adults and children aged 9 years and older, one cloth is used to wipe the underarm area once a day [1]. After application, the cloth should be disposed of, and hands should be washed [1]. It is important to avoid contact with eyes and mucous membranes [1].
What are the potential side effects of Qbrexza?
Common side effects of Qbrexza include dry mouth, dry eyes, blurred vision, and throat pain [1]. Less common side effects can include constipation, dizziness, and urinary retention [1]. In some cases, more serious side effects may occur, such as pupil dilation or central nervous system effects like confusion [1].
When can I expect Qbrexza to become available generically?
The patent exclusivity for Qbrexza may be subject to various factors including patent expiry and any potential patent challenges. Information on specific patent dates and potential generic entry timelines can be found on resources like DrugPatentWatch.com [3].
What are the alternatives to Qbrexza for treating excessive underarm sweating?
Besides Qbrexza, other treatment options for primary axillary hyperhidrosis include prescription antiperspirants, iontophoresis, and botulinum toxin injections [4]. In some severe cases, surgical options might be considered [4].
*
**Sources:
1. https://www.drugpatentwatch.com/drugs/Qbrexza
2. https://www.drugs.com/qbrexza.html
3. https://www.drugpatentwatch.com/
4. https://www.mayoclinic.org/diseases-conditions/hyperhidrosis/diagnosis-treatment/drc-20352307